Kymofic-D Tablet is a combination pharmaceutical formulation containing Diclofenac 50 mg and Trypsin Chymotrypsin 50,000 AU, designed to provide effective anti-inflammatory and analgesic therapy. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of prostaglandins responsible for pain, inflammation, and fever. Trypsin Chymotrypsin, a proteolytic enzyme complex, facilitates the breakdown of proteinaceous debris and fibrin deposits at the site of inflammation, promoting faster resolution of edema and inflammation. This synergistic combination is indicated for the management of acute musculoskeletal conditions such as sprains, strains, arthritis, postoperative inflammation, and soft tissue injuries. Kymofic-D Tablet offers rapid symptomatic relief from pain and swelling, enhancing patient mobility and comfort. It should be administered under medical supervision, with caution advised in patients with a history of gastrointestinal ulcers, bleeding disorders, or hypersensitivity to NSAIDs or enzyme preparations. The dosage regimen should be individualized based on the severity of the condition and patient response. Adverse effects may include gastrointestinal discomfort, allergic reactions, or enzyme-related hypersensitivity. Overall, Kymofic-D Tablet represents an effective therapeutic option for inflammatory and painful conditions requiring combined anti-inflammatory and proteolytic enzyme therapy.